Identification
- Summary
Technetium Tc-99m medronate is a diagnostic radiopharmaceutical agent used as a bone imaging agent to delineate areas of altered osteogenesis.
- Generic Name
- Technetium Tc-99m medronate
- DrugBank Accession Number
- DB09138
- Background
Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine imaging. It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate. Like other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of altered osteogenesis. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Technetium Tc-99m medronate (DB09138)
- Weight
- Average: 305.906
Monoisotopic: 305.861006841 - Chemical Formula
- CH6O8P2Tc
- Synonyms
- 99m Tc medronate
- 99m Tc-medronate
- 99mTc medronate
- 99mTc-medronate
- AN-MDP
- Cis-Mdp
- Tc 99m Mdp
- Tc-99m Mdp
- Technetium (99mTc) medronic acid
- Technetium (99mTc) Methylenediphosphonate
- Technetium 99mTc medronic acid
- Technetium methylene diphosphonate
- Technetium Tc 99m medronate
- Technetium Tc 99m medronic acid
- Technetium Tc 99M Mpi Mdp
Pharmacology
- Indication
Technetium Tc 99m Medronate is indicated for use as a bone imaging agent to delineate areas of altered osteogenesis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
When injected intravenously, Technetium Tc 99m Medronate is rapidly cleared from the blood; about 50% of the dose is accumulated and retained by the skeleton, while the remaining 50% is excreted in the urine within 24 hours. About 10% of the injected dose remains in the blood at 1 hour post-injection, 5% at 2 hours, and less than 1% remains at 24 hours. Following intravenous administration of Technetium Tc 99m Medronate, skeletal uptake occurs as a function of blood flow to bone and bone efficiency in extracting the complex.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Technetium Tc-99m decays by isomeric transition with a physical half-life of 6.02 hours.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Drink plenty of fluids. Void urine as frequently as possible after the examination to minimize excess radiation of the bladder.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Technetium Tc-99m medronate disodium V3V5VW82PO 65871-22-9 AXNBRPOESGBANA-KTTJZPQESA-F - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Kit for the Preparation of Technetium Tc 99M Medronate Injection, powder, lyophilized, for solution 20 mg/10mL Intravenous Sun Pharmaceutical Industries, Inc. 1979-08-29 Not applicable US 
Kit for the Preparation of Technetium Tc 99m Medronate Injection, powder, lyophilized, for solution 20 mg/1 Intravenous Cardinal Health 414, Llc 2020-12-01 Not applicable US MDP-Bracco Injection, powder, lyophilized, for solution 20 mg/1 Intravenous Bracco Diagnostics, Inc 1981-02-17 2015-05-31 US
Categories
- ATC Codes
- V09BA02 — Technetium (99mtc) medronic acid
- Drug Categories
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Diagnostic Uses of Chemicals
- Indicators and Reagents
- Laboratory Chemicals
- Organometallic Compounds
- Organophosphonates
- Organophosphorus Compounds
- Organotechnetium Compounds
- Radioactive Diagnostic Agent
- Radiopharmaceutical Activity
- Radiopharmaceuticals
- Skeleton
- Technetium (99Mtc) Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic phosphonic acids and derivatives
- Sub Class
- Bisphosphonates
- Direct Parent
- Bisphosphonates
- Alternative Parents
- Organic phosphonic acids / Organic transition metal salts / Organopnictogen compounds / Organophosphorus compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Bisphosphonate / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic salt / Organic transition metal salt / Organophosphonic acid / Organophosphorus compound / Organopnictogen compound
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X89XV46R07
- CAS number
- 121524-79-6
- InChI Key
- IUPNVOAUFBLQME-SGNQUONSSA-J
- InChI
- InChI=1S/CH6O6P2.2H2O.Tc/c2-8(3,4)1-9(5,6)7;;;/h1H2,(H2,2,3,4)(H2,5,6,7);2*1H2;/q;;;+4/p-4/i;;;1+1
- IUPAC Name
- (⁹⁸Tc)technetium(4+) ion dihydrate (phosphonatomethyl)phosphonate
- SMILES
- O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O
References
- General References
- Jiang RF, Zhang L, Cheng B, Huang Z, Li DL, Wang MM, Lu XT, Zhang YX, Cao W: Increased uptake of Tc-99m-methylene diphosphonate in the jaw. Clin Imaging. 2015 Nov-Dec;39(6):1068-72. doi: 10.1016/j.clinimag.2015.06.009. Epub 2015 Jul 16. [Article]
- Yang F, Yang Z, Feng J, Zhang L, Ma D, Yang J: Three phase bone scintigraphy with (99m)Tc-MDP and serological indices in detecting infection after internal fixation in malunion or nonunion traumatic fractures. Hell J Nucl Med. 2016 May-Aug;19(2):130-4. doi: 10.1967/s002449910366. Epub 2016 Jun 22. [Article]
- Ballani NS, Al-Huda FA, Khan HA, Al-Mohannadi S, Mahmood H, Al-Enezi F: The value of quantitative uptake of (99m)Tc-MDP and (99m)Tc-HMPAO white blood cells in detecting osteomyelitis in violated peripheral bones. J Nucl Med Technol. 2007 Jun;35(2):91-5. Epub 2007 May 11. [Article]
- External Links
- KEGG Drug
- D02029
- PubChem Compound
- 131704315
- PubChem Substance
- 310265053
- ChemSpider
- 34995234
- 1488818
- ChEBI
- 32186
- ChEMBL
- CHEMBL2110576
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Technetium_(99mTc)_medronic_acid
- FDA label
- Download (1.68 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Diagnostic Cancer 1 Not Available Completed Not Available Skeletal injury 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Intravenous 20 mg/10mL Injection, powder, lyophilized, for solution Intravenous 20 mg/1 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 13.5 mg/mL ALOGPS logP 1.03 ALOGPS logP -2.4 Chemaxon logS -1.5 ALOGPS pKa (Strongest Acidic) 1.27 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 126.38 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 23.39 m3·mol-1 Chemaxon Polarizability 10.06 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at September 30, 2015 16:19 / Updated at October 09, 2021 02:48